Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Novartis discloses several new compounds for proliferative, inflammatory conditions

Dec. 22, 1999

Soltec enters strategic alliance with Mipharm

Dec. 22, 1999

Anti-CD11a enters phase III for psoriasis

Dec. 21, 1999

Cellegy to conduct second phase III trial with Anogesic

Dec. 17, 1999

Pfizer investigates antipruritic activity of 4-phenylpiperidines

Dec. 16, 1999

Antiproliferative agents derived from vegetable oil in development at PharmaScience

Dec. 13, 1999

Dusa receives first approval of Levulan PDT for treatment of actinic keratoses

Dec. 10, 1999

Biogen reports phase II data for antipsoriatic agent and advances product to phase III

Dec. 8, 1999

Phase I/II results support the efficacy of ABX-IL-8 in psoriasis

Dec. 2, 1999

Ortec applies for FDA clearance for Composite Cultured Skin

Dec. 2, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...